Cargando…

Intravenous thrombolysis with alteplase in the treatment of acute cerebral infarction

OBJECTIVES: To compare the efficacy and safety of intravenous thrombolysis with alteplase and intravenous thrombolysis with urokinase for patients with acute cerebral infarction. METHODS: This prospective study included 140 patients with acute cerebral infarction who were admitted to our hospital be...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Lilin, Zhang, Shaojie, Wo, Xuewen, Shen, Xiangpeng, Tian, Qiangyuan, Wang, Guoqing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Professional Medical Publications 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9002439/
https://www.ncbi.nlm.nih.gov/pubmed/35480520
http://dx.doi.org/10.12669/pjms.38.3.4521
_version_ 1784685889913356288
author Gao, Lilin
Zhang, Shaojie
Wo, Xuewen
Shen, Xiangpeng
Tian, Qiangyuan
Wang, Guoqing
author_facet Gao, Lilin
Zhang, Shaojie
Wo, Xuewen
Shen, Xiangpeng
Tian, Qiangyuan
Wang, Guoqing
author_sort Gao, Lilin
collection PubMed
description OBJECTIVES: To compare the efficacy and safety of intravenous thrombolysis with alteplase and intravenous thrombolysis with urokinase for patients with acute cerebral infarction. METHODS: This prospective study included 140 patients with acute cerebral infarction who were admitted to our hospital between June 2018 and June 2019. They were randomly divided into two groups. The control group (70 cases) was treated with urokinase intravenous thrombolysis, and the observation group (70 cases) was given alteplase intravenous thrombolytic therapy. The treatment efficacy and safety of the two groups were compared. RESULTS: The total effective rate of the observation group was 95.7%, and that of the control group was 78.6%, i.e., the total effective rate of the observation group was significantly superior to the that of the control group (P < 0.05). After treatment, the observation group had significantly lower National Institutes of Health Stroke Scale (NIHSS) score and significantly higher mini-mental state examination (MMSE) score than the control group; the difference was statistically significant (P<0.05). After treatment, the levels of inflammatory factors of both groups significantly decreased compared to before treatment, and the decrease in the observation group was larger than that in the control group (P<0.05). The levels of serum homocysteine (Hcy) and monocyte chemoattractant protein-1 (MCP-1) in the observation group were significantly lower than those in the control group after treatment, and the differences were statistically significant (P<0.05). The incidence of hemorrhagic adverse reaction in the observation group was lower than that in the control group (P<0.05). CONCLUSION: In the treatment of acute cerebral infarction, ccompared with urokinase, alteplase can further relieve cognitive impairment and promote the recovery of nerve function through inhibiting levels of inflammatory factors and levels of serum Hcy and MCP-1.
format Online
Article
Text
id pubmed-9002439
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Professional Medical Publications
record_format MEDLINE/PubMed
spelling pubmed-90024392022-04-26 Intravenous thrombolysis with alteplase in the treatment of acute cerebral infarction Gao, Lilin Zhang, Shaojie Wo, Xuewen Shen, Xiangpeng Tian, Qiangyuan Wang, Guoqing Pak J Med Sci Original Article OBJECTIVES: To compare the efficacy and safety of intravenous thrombolysis with alteplase and intravenous thrombolysis with urokinase for patients with acute cerebral infarction. METHODS: This prospective study included 140 patients with acute cerebral infarction who were admitted to our hospital between June 2018 and June 2019. They were randomly divided into two groups. The control group (70 cases) was treated with urokinase intravenous thrombolysis, and the observation group (70 cases) was given alteplase intravenous thrombolytic therapy. The treatment efficacy and safety of the two groups were compared. RESULTS: The total effective rate of the observation group was 95.7%, and that of the control group was 78.6%, i.e., the total effective rate of the observation group was significantly superior to the that of the control group (P < 0.05). After treatment, the observation group had significantly lower National Institutes of Health Stroke Scale (NIHSS) score and significantly higher mini-mental state examination (MMSE) score than the control group; the difference was statistically significant (P<0.05). After treatment, the levels of inflammatory factors of both groups significantly decreased compared to before treatment, and the decrease in the observation group was larger than that in the control group (P<0.05). The levels of serum homocysteine (Hcy) and monocyte chemoattractant protein-1 (MCP-1) in the observation group were significantly lower than those in the control group after treatment, and the differences were statistically significant (P<0.05). The incidence of hemorrhagic adverse reaction in the observation group was lower than that in the control group (P<0.05). CONCLUSION: In the treatment of acute cerebral infarction, ccompared with urokinase, alteplase can further relieve cognitive impairment and promote the recovery of nerve function through inhibiting levels of inflammatory factors and levels of serum Hcy and MCP-1. Professional Medical Publications 2022 /pmc/articles/PMC9002439/ /pubmed/35480520 http://dx.doi.org/10.12669/pjms.38.3.4521 Text en Copyright: © Pakistan Journal of Medical Sciences https://creativecommons.org/licenses/by/3.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0 (https://creativecommons.org/licenses/by/3.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Gao, Lilin
Zhang, Shaojie
Wo, Xuewen
Shen, Xiangpeng
Tian, Qiangyuan
Wang, Guoqing
Intravenous thrombolysis with alteplase in the treatment of acute cerebral infarction
title Intravenous thrombolysis with alteplase in the treatment of acute cerebral infarction
title_full Intravenous thrombolysis with alteplase in the treatment of acute cerebral infarction
title_fullStr Intravenous thrombolysis with alteplase in the treatment of acute cerebral infarction
title_full_unstemmed Intravenous thrombolysis with alteplase in the treatment of acute cerebral infarction
title_short Intravenous thrombolysis with alteplase in the treatment of acute cerebral infarction
title_sort intravenous thrombolysis with alteplase in the treatment of acute cerebral infarction
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9002439/
https://www.ncbi.nlm.nih.gov/pubmed/35480520
http://dx.doi.org/10.12669/pjms.38.3.4521
work_keys_str_mv AT gaolilin intravenousthrombolysiswithalteplaseinthetreatmentofacutecerebralinfarction
AT zhangshaojie intravenousthrombolysiswithalteplaseinthetreatmentofacutecerebralinfarction
AT woxuewen intravenousthrombolysiswithalteplaseinthetreatmentofacutecerebralinfarction
AT shenxiangpeng intravenousthrombolysiswithalteplaseinthetreatmentofacutecerebralinfarction
AT tianqiangyuan intravenousthrombolysiswithalteplaseinthetreatmentofacutecerebralinfarction
AT wangguoqing intravenousthrombolysiswithalteplaseinthetreatmentofacutecerebralinfarction